Evaluation of ethanol and EDTA concentrations in the expression of biofilm-producing smf-1, rpfF genes in XDR clinical isolates of Stenotrophomonas maltophilia.
Biofilm
Checkerboard method
Clinical isolates
EDTA
Ethanol
Nosocomial infection
Stenotrophomonas maltophilia
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
30 09 2023
30 09 2023
Historique:
received:
03
06
2023
accepted:
05
09
2023
medline:
2
10
2023
pubmed:
30
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
Stenotrophomonas maltophilia is able to cause infections in immunocompromised patients, and the treatment of this opportunistic pathogen is complicated due to its virulence factors, antibiotic resistance, and the ability of the bacteria to produce biofilm. The main goals of this study were to assess the susceptibility of extensively drug-resistant (XDR) isolates to ethanol and EDTA, and evaluating the synergistic effect of these disinfectants, and also survey the effect of exposure to sub-inhibitory concentrations of ethanol and EDTA on the expression of biofilm-producing smf-1, rpfF genes. The results showed that EDTA significantly increased the effectiveness of the ethanol and have a synergistic effect. All of the 10 XDR isolates included in the current study harbored smf-1 and rpfF genes and produced biofilm. After exposure to MIC, sub-MIC, synergism, and sub-synergism of ethanol and EDTA, the expression of smf-1 and rpfF genes was repressed significantly. In the current study, it was indicated that the expression of biofilm-producing genes was repressed when bacteria are exposed to different concentrations of ethanol and EDTA. Future studies should include more complex microbial communities residing in the hospitals, and more disinfectants use in hospitals. Expression of other virulence genes in different conditions is suggested.
Sections du résumé
BACKGROUND
Stenotrophomonas maltophilia is able to cause infections in immunocompromised patients, and the treatment of this opportunistic pathogen is complicated due to its virulence factors, antibiotic resistance, and the ability of the bacteria to produce biofilm. The main goals of this study were to assess the susceptibility of extensively drug-resistant (XDR) isolates to ethanol and EDTA, and evaluating the synergistic effect of these disinfectants, and also survey the effect of exposure to sub-inhibitory concentrations of ethanol and EDTA on the expression of biofilm-producing smf-1, rpfF genes.
RESULTS
The results showed that EDTA significantly increased the effectiveness of the ethanol and have a synergistic effect. All of the 10 XDR isolates included in the current study harbored smf-1 and rpfF genes and produced biofilm. After exposure to MIC, sub-MIC, synergism, and sub-synergism of ethanol and EDTA, the expression of smf-1 and rpfF genes was repressed significantly.
CONCLUSION
In the current study, it was indicated that the expression of biofilm-producing genes was repressed when bacteria are exposed to different concentrations of ethanol and EDTA. Future studies should include more complex microbial communities residing in the hospitals, and more disinfectants use in hospitals. Expression of other virulence genes in different conditions is suggested.
Identifiants
pubmed: 37775770
doi: 10.1186/s12866-023-03008-3
pii: 10.1186/s12866-023-03008-3
pmc: PMC10542227
doi:
Substances chimiques
Edetic Acid
9G34HU7RV0
Ethanol
3K9958V90M
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
277Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Afr Health Sci. 2016 Mar;16(1):149-52
pubmed: 27358626
Biotechniques. 2004 Apr;36(4):618-20, 622, 624-6
pubmed: 15088380
BMC Microbiol. 2022 May 7;22(1):124
pubmed: 35525944
PLoS One. 2014 Oct 06;9(10):e108409
pubmed: 25285537
Food Microbiol. 2017 May;63:58-71
pubmed: 28040182
J Glob Antimicrob Resist. 2020 Dec;23:321-326
pubmed: 33137534
Front Microbiol. 2019 May 29;10:1191
pubmed: 31191502
Int J Antimicrob Agents. 2008 Dec;32(6):515-8
pubmed: 18783924
Front Microbiol. 2017 Nov 30;8:2276
pubmed: 29250041
BMC Microbiol. 2010 Apr 07;10:102
pubmed: 20374629
MethodsX. 2021 Oct 11;8:101543
pubmed: 34754811
Antimicrob Agents Chemother. 1995 Apr;39(4):921-3
pubmed: 7785996
Front Microbiol. 2018 Feb 12;9:153
pubmed: 29483899
Tanaffos. 2021 Apr;20(4):345-352
pubmed: 36267923
BMC Microbiol. 2022 May 12;22(1):129
pubmed: 35549675
Nat Rev Microbiol. 2019 Mar;17(3):141-155
pubmed: 30683887
BMC Microbiol. 2020 Oct 14;20(1):312
pubmed: 33054754
Expert Rev Anti Infect Ther. 2019 Nov;17(11):877-893
pubmed: 31658838
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
BMC Microbiol. 2011 Jul 05;11:159
pubmed: 21729271
Braz J Infect Dis. 2011 Jul-Aug;15(4):305-11
pubmed: 21860999
Braz J Infect Dis. 2016 Jul-Aug;20(4):365-73
pubmed: 27183359
BMC Res Notes. 2021 Apr 20;14(1):151
pubmed: 33879237
BMC Microbiol. 2022 Oct 21;22(1):257
pubmed: 36271327
BMC Microbiol. 2019 Apr 15;19(1):77
pubmed: 30987581
Lancet Infect Dis. 2009 May;9(5):312-23
pubmed: 19393961
BMC Microbiol. 2020 Sep 29;20(1):294
pubmed: 32993493
BMC Microbiol. 2021 Nov 8;21(1):309
pubmed: 34749674